The kingdom Animalia (animals) that consists of roughly 35 phyla of multicellular organisms.
In METAZOANS, one of the most crucial decisions that every proliferating cell must make is whether to continue another round of cell division or to exit the cell cycle and reach a quiescent state. Similarly, quiescent cells must decide whether to remain in their non-proliferative state or to re-enter the cell cycle. During early development, few cells abandon the cycle, but most of the cells in an adult organism are quiescent. Only specialized cells, such as those that populate the haematopoietic system or line the gut epithelium, maintain active proliferation. All cells have the capacity to enter quiescence and all quiescent cells -except those that have reached a state of terminal differentiation -have the capacity to re-enter the cycle, so what are the basic mechanisms that control these important decisions and how do small imbalances in these regulatory pathways lead to cancer?
Cancer cells often show alterations in the signaltransduction pathways that lead to proliferation in response to external signals. Indeed, many growth factors and their receptors, as well as their membrane, cytoplasmic and nuclear downstream effectors have been identified as oncogenes or tumour-suppressor genes. Other genes mutated in cancer include those that inactivate apoptotic pathways, induce genomic instability and promote angiogenesis. Tumour-associated mutations in many of these molecules result in the alteration of the basic regulatory mechanisms that control the mammalian cell cycle.
The basic cell cycle is divided into four phases (reviewed in REF. 1 ). During two of these phases, cells execute the two basic events in cell division: generation of a single and faithful copy of its genetic material (the synthetic or S phase) and partitioning of all the cellular components between two identical daughter cells (mitosis or M phase). The two other phases of the cycle -G1 and G2 -represent 'gap' periods, during which cells prepare themselves for the successful completion of the S and M phases, respectively. When cells cease proliferation, either due to specific antimitogenic signals or to the absence of proper mitogenic signalling, they exit the cycle and enter a non-dividing, quiescent state known as G0.
To ensure proper progression through the cell cycle, cells have developed a series of checkpoints that prevent them from entering into a new phase until they have successfully completed the previous one 2 . It is likely that newly divided or quiescent cells must also pass certain checkpoints before they can enter the cycle. For instance, cells must make sure that they have reached their homeostatic size, otherwise cells will become smaller with each round of division. Metazoans must also control the number of cells in every organ, which -coupled with cellular size -determines the size of the organism. The genetic elements that control these parameters remain largely unknown. However, they can be influenced by external elements, such as the amount of available nutrients or the intensity of the mitogenic information that cells receive at any given time (see BOX 1) . Indeed, these two parameters are key determinants for cell division. For instance, if cells have mitogenic requirements that are too stringent, they might not be able to proliferate at crucial times, such as during
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Tumour cells undergo uncontrolled proliferation, yet tumours most often originate from adult tissues, in which most cells are quiescent. So, the proliferative advantage of tumour cells arises from their ability to bypass quiescence. This can be due to increased mitogenic signalling and/or alterations that lower the threshold required for cell-cycle commitment. Understanding the molecular mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.
wound healing or during an infection. Conversely, loosening these controls might lead to unscheduled proliferation and possibly neoplastic growth. In culture, cells undergo a period of mitogen dependence before they enter the cycle. This transition -the Restriction Point (R) -represents a point of no return that commits cells to a new round of cell division (see BOX 2) . Understanding the molecular mechanisms that allow cells to enter the cycle should provide important clues as to the determinants of normal versus abnormal proliferation in multicellular organisms.
The molecular players
Cyclin-dependent kinases. Some of the molecules that control the early events of the cell cycle have been extensively characterized. The central players are the cyclin-dependent kinases (CDKs), a group of serine/threonine kinases that form active heterodimeric complexes following binding to cyclins, their regulatory subunits (reviewed in REFS 3, 4;  see ONLINE TABLE 1 ). Several CDKs -mainly CDK4, CDK6, CDK2 and possibly CDK3 -cooperate to drive cells through G1 into S phase. CDK4 and CDK6 are thought to be involved in early G1 (see below),
Box 1 | Cell growth versus cell division
Cell growth (the increase in cell size and protein mass) is a term that has frequently been misused to mean cell proliferation. In fact, both processes are highly coordinated. Only in certain biological systems -such as oocytes, neurons and muscle cells, where cell growth might exist without cell division, and in fertilized eggs, where cell divisions might occur without cell growth -can these processes function in an independent, or even complementary, fashion. In most cells, however, cell division without concurrent cell growth would generate smaller daughter cells, which would affect their viability.
Ribosome biosynthesis is a key process for cell growth. Before entering the cycle, cells need to accumulate sufficient translational machinery, mainly ribosomes, to ensure the rapid processing of transcripts through the cycle. This is accomplished, at least in part, by phosphorylation of the ribosomal S6 protein by S6 kinase (S6K) (see REF. 85 for a review). Once the appropriate pool of ribosomes has been achieved, the system is desensitized, either by negative regulators of S6K or by the size of the ribosomal pool (see figure) .
S6K is regulated by mitogenic stimuli mediated through the insulin receptor (IR)/IR substrate (IRS)/phosphatidylinositol-3 kinase (PI3K)/PDK1 pathway. S6K is also regulated directly by TOR, a member of the PI3K-related kinase family 86, 87 . TOR is thought to be important in cell growth and amino-acid sensing 87 , but its upstream activators and mechanism of activation are unknown. TOR controls several growth-related readouts, including actin organization, transcription and ribosome biosynthesis.
TOR also affects translation of key regulators of cell proliferation, such as cyclin D and MYC, by phosphorylating 4E-BP1 (a translational inhibitor that is also targeted by AKT/PKB) and causing its dissociation from the initiation factor eIF4E. Mitogen-activated protein kinases such as ERK phosphorylate and activate MNK1, which in turn is able to phosphorylate eIF4E (REFS 88, 89) . The RAS/ERK cascade is also known to signal to cellcycle regulators such as cyclin D or KIP1 to induce progression through G1 (REF. 12 ). Several of these proteins, such as PI3K, AKT, MYC and RAS, can be activated as oncogenes, which illustrates the intimate connections between cell growth and cell proliferation. ONLINE TABLE 1 ). The three members of the WAF/KIP family -WAF1 (also known as p21), KIP1 (also known as p27) and KIP2 (also known as p57) -form heterotrimeric complexes with the G1/S CDKs. However, in stoichiometric amounts, they only inhibit the kinase activity of CDK2-cyclin-E complexes (see below). CKIs are induced in response to different cellular processes 4, 17 . For instance, WAF1 is one of the effectors of p53, a tumour suppressor that is important in the DNA-damage checkpoint -a crucial process for human cancer that has been extensively reviewed elsewhere and will not be considered here.
CDK substrates. The primary substrates of CDK4/6 and CDK2 in G1 progression are the members of the retinoblastoma protein family -RB, p107 and p130 (reviewed in REFS 3, 18) . These molecules function as 'docking' sites for a series of proteins that must be tightly regulated throughout the cell cycle. For instance, RB proteins bind to the E2F family of transcription factors to ensure that they remain inactive during M and G0. In addition, RB-E2F complexes participate in active repression of some promoters: a mechanism that involves other protein families, such as histone deacetylases and chromosomal remodelling SWI/SNF complexes 19 . So far, more than 100 RB-binding proteins have been identified 20 , but the physiological relevance of most of these phosphorylated on a threonine residue (T172 in CDK4 and T160 in CDK2) -located in their T LOOP -for proper catalytic activity. This is carried out by the CDK7-cyclin-H complex (also known as CAK; CDKactivating kinase), a serine/threonine kinase that is also involved in transcription and DNA repair 10 . Inhibitory phosphorylation of adjacent threonine and tyrosine residues (T14/Y15 in CDK1) is mediated by dualspecificity kinases (such as WEE1 and MYT1). This inhibition is relieved when the CDC25 phosphatases (CDC25A, CDC25B and CDC25C) dephosphorylate these residues, which triggers entry into mitosis 3, 11 . D-type cyclins. The D-type cyclins are important integrators of mitogenic signalling, as their synthesis is one of the main end points of the RAS/RAF/MAPK PATHWAY (reviewed in REF. 12 ). Whether availability of sufficient amounts of D-type cyclins makes cells independent of mitogenic stimuli, and so allows them to pass through the R point, remains to be examined. Cyclin D1 is a rather unstable molecule that is transported from the nucleus to the cytoplasm where it is targeted -by the SCF UBIQUITIN LIGASE -for proteolysis. Nuclear export is mediated by glycogen synthase kinase 3-β (GSK-3β), a kinase that is inhibited by the RAS/PI3K/AKT PATHWAY 13, 14 . So, cyclin-D1 availability is controlled by a balance between the RAS/RAF/MAPK (cyclin-D1 synthesis) and RAS/PI3K/AKT (cyclin-D1 stability) mitogenic pathways, as well as by GSK-3β and SCF activity (cyclin-D1 degradation). Interestingly, cells that lack cyclin D1 can proliferate, indicating that this molecule is not strictly necessary for G1 (REFS 15, 16) . As the three D-type cyclins show high sequence homology and are coexpressed in many tissues, it is possible that they have at least some redundant roles. It is, however, evident (see below) that overexpression of cyclin D1 facilitates passage through G1 and promotes cell proliferation.
T LOOP
A short peptide sequencelocated between subdomains VII and VIII of protein kinases -that folds as a loop. Phosphorylation might alter its conformation and, hence, the catalytic activity of the protein kinases.
RAS/RAF/MAPK PATHWAY
Signal-transduction pathway that is crucial for the integration of mitogenic signals mediated by a variety of growth factors. Activation of this pathway is involved in many cellular processes, including cell-cycle progression.
SCF UBIQUITIN LIGASE
Multiprotein complex that ligates ubiquitin to proteins that will be degraded by the proteasome. SCF complexes consist of three core subunits (SKP1, CUL1 and RBX1) coupled to one of the several Fbox proteins that recognize the protein to be ubiquitylated.
RAS/PI3K/AKT PATHWAY
Signal-transduction pathway that is involved in many cellular processes, such as cell proliferation and apoptosis. Several members of this pathway have oncogenic or tumour-suppressor activities (for example, RAS, PI3K and PTEN).
Box 2 | The Restriction Point
The term 'Restriction Point' was coined in 1974 by Arthur Pardee 90 to define a specific event in G1 after which cultured cells could proliferate independently of mitogenic stimuli. Briefly, cultured mammalian cells that had undergone mitosis within the previous 3 hours could be prevented from progressing through the cell cycle by growth-factor starvation or moderate inhibition of protein synthesis. These cells then re-entered the cell cycle after re-stimulation with growth factors. However, if the cells had undergone cell division more than 4 hours before, they did not respond to mitogen deprivation and advanced through the cell cycle with the same kinetics as unstarved cells. It was postulated that the latter cells had 'passed' the restriction point (R). Today, R is often used to divide the early and late G1 phases.
R does not represent a checkpoint as originally defined in yeast 2, 91 . In culture cells, R occurs 3-4 hours after mitosis (see figure) . However, entry into S phase is usually initiated 5-13 hours after mitosis. This variability is characteristic of the late G1 phase and accounts for most of the observed differences in the length of the cell cycle. Indeed, the differential kinetics of these two transitions indicates distinct control mechanisms. The molecular events that allow cells to pass R have not been well defined. However, members of the RB family are likely to be important, as ablation of this gene family eliminates R 92, 93 . It has been postulated that loss of regulation of R is critical in cancer. R normally prevents cells from entering the cycle until they have accumulated a certain threshold of mitogen-induced events, so loosening of R control due to mutations in G1 regulators or other, as yet unidentified, genes would allow cells to enter the cycle even in the absence of adequate mitogenic signalling, leading to unscheduled proliferation. Validation of this model will require definition of the molecular players that regulate R. well as other hypotheses which propose that CDK4/6 kinases are important in early G1 regulation -should be re-examined in light of recent results indicating that CDK4 might be dispensable for cell-cycle commitment and proliferation
. Cdk2 has not been ablated in mice or flies. However, expression of a Cdk2 DOMINANT-NEGATIVE MUTANT (unlike similar mutants for Cdk4 and Cdk6) blocks cultured cells in G1, which illustrates the need for Cdk2 activity at the G1/S transition 26 . As indicated above, CDK2 is sequentially activated by E-type and A-type cyclins. CDK4 -and presumably CDK6 -contributes to CDK2 activation by at least two different mechanisms. First, cyclin-E1 synthesis is mediated by E2F-DP following RB phosphorylation by CDK4/6-cyclin D 22, 27 . Second, CDK4/6-cyclin-D heterodimers can bind WAF1/KIP inhibitors without losing their kinase activity [28] [29] [30] . This interaction titrates these inhibitors away from CDK2-cyclin-E complexes, which activates the CDK2 kinase 17 (FIG. 1) . These mechanisms have been at least partially corroborated in vivo by experiments with gene-targeted mice [31] [32] [33] . Replacement of the gene that encodes cyclin D1 by cyclin E1 (REF. 31 ) restores most of the phenotypic defects of cyclin-D1-defective animals 15, 16 , and as cyclin E1 cannot activate CDK4 (or CDK6), the most probable explanation is that the primary role of cyclin D1 in vivo is to activate CDK2-cyclin E1. Similarly, loss of Cdkn1b (the gene that encodes Kip1) in mice that lack cyclin D1 restores some, but not all, of their phenotypic defects 32, 33 . This differential effect could be due to the presence of Waf1, a protein that might have a redundant function with Kip1.
Cells do not rely exclusively on CDK4/6 activity to fully activate CDK2. Indeed, KIP1 is phosphorylated by CDK2 as well as by other, as yet unknown, kinases an event that triggers its PROTEASOME-mediated degradation 34, 35 . The decrease in CDK2 activity at the G1/S transition is mainly controlled by degradation of the E-type cyclins, for which a specific ubiquitin ligase, CDC4 /FBW7/AGO, has been recently identified [36] [37] [38] .
Cell-cycle mutations in human tumours
Molecular analysis of human tumours has shown that cell-cycle regulators are frequently mutated in human neoplasias (FIG. 2) , which underscores how important the maintenance of cell-cycle commitment is in the prevention of human cancer 4 . Alterations include overexpression of cyclins (mainly D1 and E1) and CDKs (mainly CDK4 and CDK6), as well as loss of CKI (mainly INK4A, INK4B and KIP1) and RB expression. Tumour-associated changes in the expression of these regulators frequently result from chromosome alterations (amplification of cyclin D1 or CDK4, translocation of CDK6 and deletions of INK4 proteins or RB) or epigenetic inactivation (methylation of INK4 or RB promoters). Miscoding mutations in CDK4 and CDK6, resulting in loss of INK4 binding, have also been identified, albeit with low frequency 39, 40 . Genetic or epigenetic alterations of CDK2 or its regulators have rarely been described in human tumours, yet interactions has not been established. The activity of the RB proteins is modulated by sequential phosphorylation by CDK4/6-cyclin-D and CDK2-cyclin-E complexes [21] [22] [23] . RB can also be regulated by acetylation, mediated by histone acetylases associated to p300/CBP. These acetylases are under cell-cycle control and prevent efficient RB phosphorylation by CDK2-cyclin E (REF. 24 ). Hyper-phosphorylated RB proteins 'release' the molecules that bind to their hypophosphorylated isoforms, allowing them to carry out their specific tasks in cell-cycle progression. CDK2 also phosphorylates other substrates that are involved in DNA replication 4, 17 .
G1 regulation in normal cells
During early G1, cells integrate external information that is derived from mitogenic stimuli and nutrient availability to prepare themselves for passing through the various phases of the cell cycle (see BOX 1) . Following generation of sufficient amounts of D-type cyclins and the subsequent CDK4/6-cyclin-D complexes, RB -and possibly other members of the RB family, depending on the cell type -becomes partially phosphorylated [21] [22] [23] , which results in the partial activation of E2F-DP transcription factors. These participate in the generation of molecules required for the G1/S transition, such as cyclin E (reviewed in REF. 20; FIG. 1 In quiescent, G0 cells, E2F-DP transcription factors are bound to p130, the principal pocket protein in these cells, which keeps them inactive. In G1, however, RB-E2F-DP complexes predominate. Mitogenic signalling results in cyclin D (Cyc) synthesis, formation of active CDK4/6-cyclin-D complexes and initial phosphorylation of RB. Partially phosphorylated RB still binds to E2F-DP, but the transcription factor is still able to transcribe some genes, such as cyclin E, presumably due to impaired repression. Cyclin E binds to and activates CDK2. It is generally accepted that CDK2-dependent phosphorylation of RB results in its complete inactivation, which allows induction of the E2F-responsive genes that are needed to drive cells through the G1/S transition and to initiate DNA replication. INK4 and WAF1/KIP proteins can inhibit CDK4/6 or CDK2 kinases, respectively, following specific antimitogenic signals. The CDK4/6 complexes can also bind WAF1/KIP inhibitors, while remaining active. This sequesters them from CDK2, which facilitates its full activation. R represents the restriction point that separates the mitogendependent early G1 phase from the mitogen-independent late G1 phase.
cells is not yet well understood. KIP1 degradation is mediated, at least in part, by SKP2 -an F-BOX PROTEIN of the SCF complex. SKP2 has oncogenic properties and its expression is altered in some tumour cells 41, 42 . Similarly, loss of CDKN1B (the gene that encodes KIP1 in humans) expression, and overexpression of cyclin E1 frequently occur and correlate with poor prognosis (FIG. 2) . How KIP1 and cyclin-E1 expression is altered in tumour . Cdk4 mutant flies develop normally and eclose at the same time as normal flies. However, they are smaller in size due to the presence of fewer cells, rather than to a decrease in cell size. The slower growth rate could mean that cells take longer to reach the size requirement for division. So, Cdk4 seems to regulate homeotic cell numbers, but is not necessary for cell proliferation. In mice, Cdk4 is also dispensable for proliferation in most cell types 7, 8 . Cdk4-null mice are also significantly smaller. Whether this phenotype is due to the generation of fewer cells or to hormonal or other physiological abnormalities is not known. Proliferating mouse embryo fibroblasts (MEFs) that lack Cdk4 have normal (or almost normal) cell-cycle profiles 7, 8 , which could be a consequence of the redundant roles of Cdk4 and Cdk6 in mice.
Conversely, gain-of-function experiments indicate that Cdk4 and cyclin D1 stimulate cell proliferation. For instance, fruitflies that overexpress Cdk4-cyclin D display hyperplastic proliferation of normal-size cells in some tissues 95, 96 .
Cyclin-D1 overexpression also induces tumours
60
, and is a key mediator of breast-cancer induction by Ras or Neu oncogenes
97
. Similarly, mice that express a knocked-in Cdk4 mutant that cannot be downregulated by INK4 inhibitors develop tumours with almost complete penetrance 58 and have a high susceptibility to develop melanomas
59
. These results indicate that although Cdk4 is dispensable for cell proliferation, its misregulation facilitates cell proliferation and contributes to neoplastic development ( see FIG. 2 ).
Animal models
Genetically modified mice have provided new insights into the roles of cell-cycle regulators in both normal and pathological processes. Early gene-targeting studies showed that Rb deficiency is lethal in mouse embryos, whereas Rb +/-mice develop tumours of endocrine origin (pituitary, thyroid and adrenal medulla) 45, 46 . By contrast, deletion of the other members of this familyp107 or p130 -has few or no effects on mouse embryonic development or tumour susceptibility (reviewed in REF. 47 ). Combined deficiency of Rb +/-and p107, however, causes retinoblastoma in the mouse, showing that these proteins partially overlap in tumour suppression 48 . Ablation of KIP1 results in ORGANOMEGALY and a high penetrance of pituitary tumours [49] [50] [51] . In addition, this protein is HAPLO-INSUFFICIENT for tumour suppression 52 , indicating a functional effect for the low levels of KIP1 expression that are frequently observed in human tumours (FIG. 2) . Mice deficient fo Cdkn1a (which encodes Waf1) also develop a variety of tumours (mainly sarcomas and B-cell lymphomas), although these tumours have a long latency period 53 . Genetic studies have also shown that deletion of Cdkn2a (the gene that encodes Ink4a in mice) 54, 55 or Cdkn2b (the gene that encodes Ink4b in mice) 56 results in low, the F-box protein responsible for cyclin-E1 degradation -CDC4/FBW7/AGO -is inactivated in some cancer cell lines 36, 37 . Alternatively, cancer-associated cyclin-E overexpression could be explained by RB inactivation, which is mediated by deregulated CDK4/6 activity. Recently, a new cell-cycle inhibitory protein that enhances WEE1-dependent phosphorylation of CDK2, named Cables, has been reported to be inactivated in 50-60% of primary colon and head and neck tumours 43 . Loss or inactivation of RB is a frequent event in human tumours. However, p130 is less frequently lost and p107 inactivation has not been reported (reviewed in REF. 44 ). These observations indicate that p107 and p130 might be important for differentiation rather than proliferation, a concept supported by results obtained with gene-targeted mice (see below). Mutations in the E2F family of transcription factors have not been observed in human tumours.
Recently, mutations in cell-cycle regulators that do not affect cell growth or cell proliferation have been identified (see BOX 4) . These mutations appear in molecules that are involved in the control of sister-chromatid separation during mitosis, and are likely to induce aneuploidy as well as other chromosomal alterations, that will contribute to the transformed phenotype. 
HAPLO-INSUFFICIENCY
A phenotype that arises in diploid organisms due to the loss of only one allele.
Box 4 | Other cell-cycle mutations in cancer
Losing control of the commitment to cell division seems to be an important step in the progression of human cancer. However, it is possible that misregulation of other cell-cycle events might also contribute to neoplasia. After all, chromosomal instability and aneuploidy, two prominent consequences of defective M-phase checkpoints, are hallmarks of cancer cells. The proper distribution of chromosomes is controlled at the metaphaseto-anaphase transition by the spindle-assembly checkpoint (see figure, a; and REFS 98, 99 for recent reviews). The gatekeeper of this checkpoint is the anaphase-promoting complex (APC), a multisubunit ubiquitin ligase that, with CDC20, targets proteins such as securin for degradation. If the  kinetochores are correctly attached to the spindle, APC is activated and securin is degraded. This activates the separin protease, which cleaves the  cohesin molecules between sister chromatids, allowing them to separate. However, if the kinetochores are not correctly attached to the spindle, APC is  kept in an inactive state and cells arrest in metaphase (see figure, b) . APC activity is primarily regulated by MAD2, which senses microtubule attachment to the kinetochores. Although the mechanisms that regulate MAD2 activity are not fully understood, they have implicated, among other proteins, the BUB family of kinases 99 . BUB1 has been found mutated in colon cancer cell lines However, the best strategies to accomplish these goals have not been determined, and will require proper experimentation in adequate animal models (see above) and, ultimately, in clinical trials.
CDKs are actively being targeted, due to their central role in the control of cell-cycle progression. The complexity of CDK regulation offers a number of possible routes to their therapeutic inhibition (FIG. 3) . The most direct and promising strategies involve designing inhibitors that block CDK activity (TABLE 1) . The clinical success of STI-571 -an inhibitor of the ABL kinase -in the treatment of chronic myelogenous leukaemia (CML) has provided hope that this type of strategy can work. Other strategies that have good probabilities of success include preventing cyclin-CDK interaction with peptidomimetics or multifunctional chemical structures -for example, derived from a structure-activity relationship by nuclear magnetic resonance analysis 67 , restoring CKI function by gene therapy 68 , or by using peptidomimetics 69 and preventing CKI degradation. In those cases in which CKI loci have been silenced by epigenetic events, CKI expression could be restored by demethylating agents such as 5′-deoxyazacytidine (5-dAZA) that prevent promoter methylation -5-dAZA has antitumour activity in leukaemia and other neoplasias 70 . Alternative strategies to prevent degradation of CKIs such as KIP1 could involve although significant, susceptibility to tumour development. Conversely, mice that are null for Cdkn2c (the gene that encodes Ink4c in mice) develop pituitary tumours with high penetrance 56, 57 . Importantly, knockin mice that express a Cdk4 mutant originally found in human melanoma 39 and that is insensitive to INK4 inhibitors (Cdk4 R24C) develop several tumours in a variety of tissues 58 and display high susceptibility to melanoma development 59 . Similarly, overexpression of cyclin D1 or cyclin E1 in transgenic mice also leads to tumour development 60, 61 . As observed in human cancer (FIG. 2) , alterations in different families of cell-cycle regulators cooperate in tumour development. So, deficiency in RB cooperates with ablation of WAF1/KIP proteins 62, 63 . In addition, lack of WAF1 or KIP1 synergizes with the absence of INK4 proteins 57, 64 or the CDK4 R24C mutation 58 .
Therapeutic strategies
The frequent loss of G1 regulation in human cancer has revealed targets for possible therapeutic intervention. Indeed, restoring proper R-point control to cancer cells might allow them to return to a quiescent state. Alternatively, we could take advantage of their uncontrolled proliferation to facilitate apoptotic death 65 or to specifically expose cancer cells to cytotoxic treatments 66 . 
CINK4
Triamino-CDK4/6-cyclin D1 Causes RB dephosphorylation and growth arrest 116 pyrimidine in culture and smaller tumours in a xenograft model.
PD 0183812
Pyrido-pyrimidine CDK4, CDK6 > CDK2 G1 arrest in RB-positive cells, in correlation with 117 RB hypophosphorylation.
Fascaplysin
Natural product CDK4 G1 arrest and RB dephosphorylation at sites that are 118 specific for CDK4 kinase.
Asterisks refer to compounds tested in clinical trials. CDK, cyclin-dependent kinase; RB, retinoblastoma.
inhibitors that also inhibit CDKs. Conversely, flavopiridol, olomucine, butyrolactone-1 and paullones are more selective for CDK inhibition (see TABLE 1 and REFS 77,78 for reviews). Assuming that the specificity issue could be resolved, therapeutic strategies must also take into account which CDK is the best target. Although most mutations in human cancer affect CDK4 and CDK6 or their regulators (FIG. 2) , current drug-discovery efforts favour the design of either PAN-CDK INHIBITORS or inhibitors that are specific for CDK2. This is not surprising as clinical investigators are more concerned with achieving potent cell-killing activity than target specificity.
Indirubin -an active ingredient of a traditional Chinese recipe given to patients with CML -was the first example of a CDK inhibitor that was used to treat human cancer 79 , and flavopiridol -a flavonoid derived from an indigenous plant from India -was the first CDK modulator tested in clinical trials. Early-phase trials have shown activity in some patients with non-Hodgkin's lymphoma, and renal, prostate, colon and gastric carcinomas (reviewed in REF. 80 ). Another CDK inhibitor tested in clinical trials, UCN-01, has shown activity in patients with melanoma, lymphoma and sarcomas 80 . UCN-01 is able to block the cell cycle and to abrogate checkpoints that are induced by genotoxic stress, due to modulation of the CHK1 kinase. In addition, UCN-01, along with other CDK inhibitors, induces apoptosis (TABLE 1) . Although much more work needs to be done in this area, it is probable that this activity is mediated by E2F. As CDK2 activity is required for the dissociation of E2F from DNA, CDK2 inhibition might result in E2F activity persisting beyond S phase, which could lead to apoptosis. This circumstance could also be exploited to specifically kill transformed cells in which E2F activity is upregulated 65 . Trials of CDK inhibitors in combination with other chemotherapy agents are being considered. In addition, chemical inhibition of CDKs might spread to other areas of medicine. For instance, CDK inhibitors are being studied in nephrology, cardiovascular diseases, neurodegenerative disorders and even in the fight against unicellular parasites and viral diseases (for reviews, see REFS 81, 82) .
Apart from these considerations, we must not forget that some of the most widely used antitumour drugs -the taxanes and the vinca alkaloids -inhibit the cell cycle by altering the mitotic spindle 83 . Whereas the vinca alkaloids depolymerize microtubulesthereby increasing the soluble tubulin pool -the taxanes (and also a new class of promising antitumour drugs, the epothilones 83, 84 ) stabilize microtubules, thereby increasing the microtubular mass. In spite of these obvious mechanistic differences, they might have a similar end-point activity -the induction of apoptotic death due to activation of the spindle checkpoint. Understanding the molecular bases for the differential effect of these compounds on tumour versus normal cells should open new windows of opportunity to improve current therapeutic strategies. either blocking phosphorylation, which triggers its degradation, or its interaction with SKP2, one of the members of the SCF complex. Some proteasomal inhibitors such as PS-341 have shown interesting results in clinical trials, in spite of their obvious lack of specificity 71 . Other strategies that have been less explored and/or are less likely to succeed include decreasing levels of cyclin D1 or cyclin E by reducing specific transcription of these genes by antisense techniques 72 or increasing degradation of these proteins by stimulating signals (phosphorylation) recognized by their specific proteasomes. Downregulating positive regulators, such as the CDK-activating kinase (CAK) or the CDC25 dualspecificity phosphatases, are also viable strategies 73 . Finally, activating negative regulators, such as the dualspecificity kinases WEE1 or MYT1, might also yield anti-proliferating or pro-apoptotic benefits.
Resolution of the tertiary structure of CDKs bound to their cognate cyclins or to CKIs (reviewed in REF. 74) is facilitating the design of small-molecule inhibitors 75 (TABLE 1). Yet current strategies tend to target the ATPbinding site that is necessary for their kinase activity. Unfortunately, catalytic residues are well conserved across eukaryotic protein kinases, which makes adequate specificity a big challenge as there are more than 500 protein kinases in the human genome 76 . For instance, staurosporines, suramin and 6-dimethylaminopurine are relatively nonspecific protein kinase PAN-CDK INHIBITORS CDK inhibitors that do not discriminate between different CDKs. These drugs can frequently inhibit other protein kinases. how cells coordinate cell growth and cell proliferation, and how they decide whether to cycle or not to cycle, is a greater challenge. Ultimately, the design of highly specific and effective anticancer drugs should come from multidisciplinary approaches that combine, among other strategies: molecular pathology, to identify all the mutations/alterations present in human tumours; functional genomics, to select the most important targets; structural and computational biology, to predict protein structure and target-inhibitor interactions; computer-assisted combinatorial chemistry, to design the best possible inhibitors; and animal models with high predictability value, to increase the chances of success of leading drug candidates in the clinic -the ultimate test.
Conclusions
Cancer is frequently considered to be a disease of the cell cycle. Although many specific cell-cycle regulatory mechanisms have been studied in depth in vitro, it is still unclear how diverse cellular processes are coordinately deregulated with cell division in human cancer. An integrated view from biochemical studies, experimental animal models and the analysis of cancer mutations will undoubtedly help to exploit this knowledge in therapeutic approaches. Future research should focus on crucial aspects of cell-cycle regulation in vivo, such as the pathways of synthesis and proteolysis of essential proteins, post-translational regulations and, importantly, the functional specificity or redundancy among family members. Similarly, explaining
